Oct 23, 2019 / 07:30AM GMT
Operator
Ladies and gentlemen, welcome to the BioGaia Q3 report 2019. Today, I am pleased to present Isabelle Ducellier, CEO. (Operator Instructions)
Speakers, please begin.
Isabelle Valerie Ghislaine Ducellier - BioGaia AB(publ)-CEO
Yes, good morning, Isabelle speaking, and thank you for joining BioGaia's telephone conference regarding Q3 2019.
Next page, please. Regarding the quarter 3, we have, unfortunately, a sales decrease of 4% and that is due mainly to the decrease of royalty that we have been speaking about for the quarter, but as well a new item that we didn't focus, a delivery delay coming from our supplier of aluminum blister in Belgium, namely Sanico. So despite the Sanico problem, we have pretty good growth in Adult segment with 8%, with a modest sales growth of our products in Pediatrics by 3%. We have good sales for our Protectis drops not affected by Sanico at all as we produce our drops at Eslöv in the south of Sweden. And despite Sanico, we managed anyway to have a good sales of Gastrus tablets and
Q3 2019 Biogaia AB Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot